Januel, Edouard http://orcid.org/0000-0003-0108-4720
Brochard, Vincent
Le Guennec, Loïc
Maillart, Elisabeth
Louapre, Céline
Lubetzki, Catherine
Weiss, Nicolas
Demeret, Sophie
Papeix, Caroline
Clinical trials referenced in this document:
Documents that mention this clinical trial
Risk factors and prognosis of orotracheal intubation in aquaporin-4-IgG neuromyelitis optica spectrum disorder attacks
https://doi.org/10.1186/s13613-023-01213-x
Article History
Received: 14 July 2023
Accepted: 14 November 2023
First Online: 8 January 2024
Declarations
:
: All patients gave their written informed consent. This was a retrospective observational monocentric cohort study nested in the NOMADMUS cohort (ClinicalTrials.gov Identifier: NCT02850705). This registry was approved by a French ethical committee (Comité de Protection des Personnes [CPP]: reference 2019-Ă6-51). This study was recorded in the registry of processing operations of Assistance Publique—Hôpitaux de Paris (No. 20210419181607), in accordance with the Commission Nationale de l'Informatique et des Libertés (CNIL).
: Not applicable.
: Edouard Januel has no disclosure to declare; Vincent Brochard has no disclosure to declare; Loïc Le Guennec has no disclosure to declare; Elisabeth Maillart has received research support from Fondation ARSEP and Biogen Idec, travel funding and/or consulting fees from Alexion, Biogen Idec, BMS, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva; Celine Louapre has received consulting or travel fees from Biogen, Novartis, Roche, Sanofi, Teva and Merck Serono, and research grant from Biogen; Catherine Lubetzki has participated in advisory boards for Roche, Biogen, ReWind and Merck and received research support from Merck Serono; Nicolas Weiss has received consulting fees from Owkin and Alexion; Sophie Demeret received honoraria and consulting fees from Alexion, UCB, Régénéron, Roche and ARGENX; Caroline Papeix received honoraria and consulting fees from Alexion, Biogen, Merck and Roche.